Research [Member]
Finite Lived Intangible Assets By Major Class [Axis]
Patents [Member]
Drug [Member]
Pharmaceutical [Member]
PatentedTechnologyMember
Intangible Assets [Member]
Franklin [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Philadelphia2 [Member]
Manfc Lab Office [Member]
Real Estate Property Ownership [Axis]
Apartment [Member]
Property, Plant and Equipment, Type [Axis]
SeriesCPreferredStock [Member]
Statement Class Of Stock [Axis]
SeriesDPreferredStock [Member]
Plan2003Member
Plan Name [Axis]
Plan2008Member
Not Pursuant to a Plan [Member]
PlacementAgents1 [Member]
Class of Warrant or Right [Axis]
Exp 8/31/2017 Warrant [Member]
Exp 9/20/2017 Warrant [Member]
Investors1 [Member]
Exp 11/6/2017 Warrant [Member]
PreferredStock1 [Member]
PreferredStock2 [Member]
PreferredStock3 [Member]
Vendor 1 [Member]
Investors3 [Member]
Grantedtovendor2Member
Investors4 [Member]
Investors5 [Member]
Investors6 [Member]
Investors7 [Member]
Investors8 [Member]
PlacementAgents2 [Member]
PlacementAgents3 [Member]
Investors9 [Member]
Investors10 [Member]
Investors11 [Member]
Investors12 [Member]
PlacementAgents4 [Member]
PlacementAgents5 [Member]
Investors13 [Member]
Investors14 [Member]
PlacementAgents6 [Member]
PlacementAgents7 [Member]
Investors15 [Member]
Investors16 [Member]
PlacementAgents8 [Member]
PlacementAgents9 [Member]
Investors17 [Member]
Investors18 [Member]
Investors19 [Member]
TotaloutstandingwarrantsaccountedforasequityMember
WeightedaverageexercisepriceMember
WeightedaveragetimetoexpirationinyearsMember
ProductDevelopment [Member]
Restricted Cash and Cash Equivalents [Axis]
Landlord [Member]
Jan31Aegis [Member]
Line of Credit Facility [Axis]
Vendors [Member]
Share-based Goods and Nonemployee Services Transaction, by Supplier [Axis]
FDA Approval [Member]
VestingCondition [Axis]
Sale of Company [Member]
Yearly [Member]
Philadelphia [Member]
Handok [Member]
Principal Transaction Revenue, Description of Reporting Category [Axis]
EqPlan 2003 [Member]
EqPlan 2008 [Member]
Product Development 2 [Member]
January [Member]
Securities Financing Transaction [Axis]
June [Member]
Preferred Stock
Statement, Equity Components [Axis]
Common Stock
Additional Paid-In Capital
Common Stock Subscribed
Accumulated Deficit
Computer Equipment [Member]
Office Equipment [Member]
Furniture and Fixtures [Member]
Manufacturing Equipment [Member]
Leasehold Improvements [Member]
Office Equipment Max [Member]
Series B Preferred Stock [Member]
Series E Preferred Stock [Member]
Statement Class of Stock [Axis]
December 2013 [Member]
Equity Components [Axis]
Accumulated Deficit
Series C Preferred Stock [Member]
Series D Preferred Stock [Member]
Not Pursuant to Plan [Member]
Minimum [Member]
Range [Axis]
Maximum [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement [Table]
Statement [Line Items]
ASSETS
Current Assets:
Cash and cash equivalents
Cash restricted pursuant to letters of credit
Current portion of deferred financing costs
Prepaid expenses and other current assets
Total current assets
Property and Equipment, at cost:
Computer equipment
Office and laboratory equipment (including assets under capitalized leases)
Furniture and fixtures
Manufacturing equipment
Leasehold improvements
Property and equipment, at cost
Less-Accumulated depreciation and amortization
Net property and equipment (including assets under capitalized leases)
Other Assets:
Restricted cash
Intangible assets, net of accumulated amortization
Deferred financing costs
Other assets
Total other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable
Current portion of deferred revenue from licensing arrangements
Current portion of capital lease obligation
Derivative warrant liability
Accrued expenses and other liabilities
Total current liabilities
Deferred revenue from licensing arrangements, net of current portion
Total liabilities
Commitments and contingencies
Stockholders' Equity:
Convertible Preferred Stock:
Series C, $0.01 par value, authorized 10,000 shares, issued and outstanding 1,000 shares at June 30, 2014 and December 31, 2013; Series D, $0.01 par value, authorized 3,600,000 shares, issued and outstanding 1,000,000 shares at June 30, 2014 and December 31, 2013 (preference in liquidation of $1,000,000); Series E, $0.01 par value, authorized 1,748,613 shares, issued and outstanding 1,748,613 shares at March 31June 30, 2014 and December 31, 2013
Common Stock, $0.01 par value, authorized 150,000,000 shares, issued and outstanding 12,665,518 and 11,776,578 shares at June 30, 2014 and December 31, 2013, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity
Convertible Preferred Stock, par value
Convertible Preferred Stock, authorized
Convertible Preferred Stock, outstanding
Convertible Preferred Stock, Share Issued
Convertible Preferred Stock,preference in liquidation
Common stock, par value
Common stock, authorized
Common stock, outstanding
Common stock, Share Issued
Income Statement [Abstract]
Licensing revenue
Total revenues
Operating Expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other Income (Expense):
Interest income
Interest expense
Gain on disposals of assets
Gain on revaluation of derivative warrant liability
Other income (expense), net
Net loss
Net loss per common share, basic and diluted
Basic and diluted weighted average common shares outstanding
Statement of Cash Flows [Abstract]
Cash Flows From Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Share-based compensation, net
Fair value of common stock and warrants issued for services
Gain on revaluation of derivative warrant liability
Gain on disposal of assets
Amortization of discount on note payable
Amortization of non-cash deferred financing costs
Changes in assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Deferred revenue from licensing arrangements
Accrued expenses and other liabilities
Net cash used in operating activities
Cash Flows from Investing Activities:
Purchase of furniture, equipment and leasehold improvements
Decrease (increase) in restricted cash
Proceeds on disposal of furniture, equipment and leasehold improvements
Net cash used in investing activities
Cash Flows From Financing Activities:
Proceeds from issuances of Common Stock, and warrants, net of expenses
Repayment of Montaur note payable
Principal payments on capital lease obligations
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental Disclosure of Cash Flow Information and Non Cash Financing Transactions:
Cash paid for interest
Notes to Financial Statements
Note 1. ORGANIZATION AND BASIS OF PRESENTATION
Note 2. CASH
Note 3. INTANGIBLE ASSETS
Note 4. OPERATING LEASE COMMITMENTS
NOTE 5. CREDIT FACILITY WITH PLATINUM-MONTAUR LIFE SCIENCES, LLC
Note 6. DERIVATIVE WARRANT LIABILITY
Note 7. PREFERRED STOCK
Note 8. COMMON STOCK
Compensation and Retirement Disclosure [Abstract]
Note 9. EQUITY COMPENSATION PLANS
Note 10. STOCK OPTIONS
Note 11. RESTRICTED STOCK
Note 12. WARRANTS
Note 13. LICENSING AND OTHER REVENUE
Commitments and Contingencies Disclosure [Abstract]
NOTE 14. LITIGATION
Subsequent Events
Note 15. SUBSEQUENT EVENTS
Organization And Basis Of Presentation Policies
ORGANIZATION AND BASIS OF PRESENTATION
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLAN
RECLASSIFICATIONS
Intangible Assets Tables
Intangible assets
Amortization expense
Operating Lease Commitments Tables
Future minimum lease payments
Derivative Warrant Liability Tables
Derivative warrant liability
Share based compensation options
Stock Options Tables
Assumption used for stock option granted
Stock option activity
Nonvested restricted stock activity
Warrants Tables
Warrants assumptions utilized by the Company
Outstanding Warrants
Warrant Activity
Organization And Basis Of Presentation Details Narrative
Organization And Basis Of Presentation
Reverse stock split ratio
Liquidity and Management's Plans
Cash
Working capital deficit
Accumulated deficit
Net cash proceeds from financing
Financing total amount
Shares of stock issued in financing
Warrants issued in financing
Notes to Financial Statements
Cash And Cash Equivalents
Letter of credit, landlord
Letter of credit, vendor
Finite-Lived Intangible Assets by Major Class [Axis]
Intangible assets
Cost
Accumulated Amortization
Total
Intangible Assets Details 1
Estimated amortization expense
2014
2015
2016
2017
2018
Schedule of Operating Leased Assets [Table]
Operating Leased Assets [Line Items]
OPERATING LEASE COMMITMENTS
Year ended December 31, 2014
Year ended December 31, 2015
Year ended December 31, 2016
Year ended December 31, 2017
Year ended December 31, 2018
Total
Operating Lease Commitments
Leased space square footage
Facilities lease expense
Right to early lease termination buy out value
Loan agreement initial credit facility
Loan agreement Maximum Draw Amount
Principal interest rate per annum
Cash and cash equivalent minimum requirements on credit facility
Commitment warrant value, shares
Fair value Commitment warrant, recorded as deferred financing costs
Commitment warrant exercise price
Fair value Commitment warrant, current portion
Amortization of fair value Commitment warrant
Funds borrowed pursuant to the Credit Facility
Purchase warrant value per 1,000,000 borrowed amount, shares
Commitment Warrant exercise price maximimum
Commitment Warrant exercise price minimum
Commitment Warrant beneficial ownership maximum
Commitment Warrant beneficial ownership minimum
Loan agreement September Request
September Request warrant issued
Warrant exercise price September Request
Warrant exercise price September Request, maximum
Fair value September Request
Debt Discount
Interest Expense
Repayment of outstanding draws
Interest accrued
Non-cash interest expense
Derivative Warrant Liability Details
DERIVATIVE WARRANT LIABILITY
Beginning balance
Total unrealized losses included in net loss
Total unrealized gains included in net loss
Total realized gains included in net loss
Reclassification of derivative warrant liability to additional paid-in capital for derivative warrants exercised
Ending balance
Derivative Warrant Liability Details Narrative
Outstanding warrants
Derivative financial instruments
Fair value of derivative instruments on recurring basis
Gain/Loss on Revaluation of Derivative Warrant Liability
Schedule of Stock by Class [Table]
Class of Stock [Line Items]
Class of Stock [Axis]
Authorized Preferred Stock
Issued and outstanding
Common stock, shares authorized
Common stock, Shares outstanding
Common Stock public offering
Shares purchased
Shares sold pursuant to over-allotment
Share sale price
Series E Preferred Stock purchased
Platinum Securities Purchase Agreement warrants
Net proceeds from sale of shares in public offering
Total balance paid off
Principal balance
Accrued and unpaid interest balance
Gross proceeds
Issuance costs
Stock issuance costs to paid in capital
Stock issued in exchange for services
Fair value of stock issued in exchange for services
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation
Shares Available For Issuance
Total reserved for stock options and restricted stock
Net restricted stock issued net of cancellations
Stock options granted
Add back options cancelled before exercise
Options cancelled by plan vote
Remaining shares available for future grants
Outstanding Options and Restricted Stock
Total granted
Options cancelled
Options exercised
Net shares outstanding before restricted stock
Net restricted stock issued net of cancellations
Ending Balance
Stock Options And Restricted Stock
Restricted shares of Common Stock issued
Options to purchase an aggregate of shares
Maximum authorized shares
Shares Future grants
Stock Options Details 1
STOCK OPTIONS AND RESTRICTED STOCK
Risk-free interest rate minimum
Risk-free interest rate maximum
Expected dividend yield
Expected term, minimum
Expected term, maximum
Forfeiture rate (excluding fully vested stock options) minimum
Forfeiture rate (excluding fully vested stock options) maximum
Expected volatility
Expected volatility
Stock Options Details 2
Stock Options
Shares
Beginning Balance
Granted
Exercised
Forfeited or expired
Ending Balance
Exercisable at March 31, 2014
Weighted-Average Exercise Price
Beginning Balance
Granted
Exercised
Forfeited or expired
Ending Balance
Exercisable at March 31, 2014
Weighted-Average Remaining Contractual Term
Beginning Balance
Ending Balance
Aggregate Intrinsic Value
Beginning Balance
Ending Balance
Stock Options Details Narrative
Weighted-average grant-date fair value of stock options granted
Total unrecognized compensation expense
Additional paid-in capital
Non-cash compensation expense
STOCK OPTIONS AND RESTRICTED STOCK
Shares
Nonvested at January 1, 2014
Granted
Vested
Forfeited
Nonvested at June 30, 2014
Weighted- Average Grant-DateFair Value
Nonvested at January 1, 2014
Granted
Vested
Forfeited
Nonvested at June 30, 2014
VestingConditionAxis [Axis]
Stock Options And Restricted Stock
Non-cash compensation expense
Aggregate restricted shares of Common Stock pursuant to 2008 plan
Shares of non-vested restricted stock
Restricted stock to vest upon FDA approval
Total unrecognized compensation expense
Warrants Details
Risk-free interest rate
Risk-free interest rate, maximum
Expected dividend yield
Expected term (contractual term)
Expected term (contractual term), maximum
Forfeiture rate
Expected volatility
Expected volatility, maximum
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Warrants
Number of Shares Exercisable
Exercise Price
Total outstanding warrants accounted for as derivative warrant liability
Weighted average exercise price
Weighted average time to expiration in years
Number of Shares Exercisable
Exercise Price
Total Warrants Outstanding
Total Weighted average exercise price
Warrants Details 3
Warrants
Shares
Beginning Balance
Granted
Exercised
Forfeited or expired
Ending Balance
Weighted-Average Exercise Price
Beginning Balance
Granted
Exercised
Forfeited or expired
Ending Balance
Warrants Details Narrative
Warrants issued in connection with private placement
Licensing and Other Revenue
Minimum licensing term
Nonrefundable license revenue
Licensing fee relating to Handok
Deferred revenue recognized over next twelve months
Deferred revenue to be recognized after next twelve months
Net cash proceeds from MTIA Common Stock financing
Total MTIA investment
Additional proceeds from MTIA financing
Deemed dividend on beneficial conversion feature of Series D Convertible Preferred Stock
Note 5. DERIVATIVE WARRANT LIABILITY
Basic and diluted weighted average common shares outstanding
Apartment.
Note 5. DERIVATIVE WARRANT LIABILITY
Document And Entity Information
Fair value of common stock and warrants issued for services
Notes to Financial Statements
OfficeAndLaboratoryEquipment
Convertible Preferred Stock:Series C, $0.01 par value, authorized 10,000 shares, issued and outstanding 9,974.185 shares at March 31, 2012 and December 31, 2011
Convertible Preferred Stock:Series C, authorized
Convertible Preferred Stock:Series C, outstanding
Convertible Preferred Stock: Series C, par value
Convertible Preferred Stock:Series D, $0.01 par value, authorized 3,600,000 shares, issued and outstanding 3,006,000 shares at March 31, 2012 and December 31, 2011 (preference in liquidation of $3,006,000 at March 31, 2012)
Convertible Preferred Stock:Series D, authorized
Convertible Preferred Stock:Series D, outstanding
Convertible Preferred Stock:Series C, $0.01 par value, authorized 10,000 shares, issued and outstanding 9,974.185 shares at March 31, 2012 and December 31, 2011
Convertible Preferred Stock:Series D, par value
Convertible Preferred Stock:Series D, Share Issued
Note 9. WARRANTS
CreditFacilityPlatinumMontaurLifeSciencesTextBlock
DebtHolderAcquisition1Member
DebtHolderAcquisition2Member
Custom Element.
Note 5. DERIVATIVE WARRANT LIABILITY
Document And Entity Information
Custom Element.
EQ Plan 2003.
EQ Plan 2008.
FDAApprovalMember
FairValueCommitmentWarrantCurrentPortion
FairValueCommitmentWarrantRecordedAsDeferredFinancingCosts
Fair value of common stock and warrants issued for services
FairValueSeptemberRequest
Custom Element.
Custom Element.
FundsBorrowedPursuantToCreditFacility
GainLossOnRevaluationOfDerivativeWarrantLiability
Custom Element.
Custom Element.
Custom Element.
Grantedtoinvestorsinprivateplacement12Member
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Handok.
Custom Element.
Investors1Member
Jan31AegisMember
LandlordMember
LicensingAndOtherRevenue
LoanAgreementInitialCreditFacility
LoanAgreementMaximumDrawAmount
LoanAgreementSeptemberRequest2
Minimum licensing term.
Mnfc Lab Office.
Custom Element.
Custom Element.
Notes to Financial Statements
OfficeAndLaboratoryEquipment
Custom Element.
Custom Element.
Custom Element.
PlacementAgents1Member
Custom Element.
Custom Element.
PrincipalInterestRatePerAnnum
ProductDevelopmentMember
PurchaseWarrantValuePer1000000BorrowedAmountShares
Reclassification of derivative warrant liability to additional paid in capital for derivative warrants exercised.
Custom Element.
RepaymentOfOutstandingDraws
Custom Element.
RestrictedStockTextBlock
SaleOfCompanyMember
ScheduleOfStockOptionActivity
SeptemberRequestWarrantIssued1
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Shares.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
VendorsMember
VestingConditionAxis
WarrantActivity
WarrantExercisePriceSeptemberRequest2
Warrants details outstanding.
Note 9. WARRANTS
Custom Element.
Weighted average grant date fair value.
Weighted average exercise price.
Custom Element.
Custom Element.
Custom Element.
YearlyMember
Retained Earnings [Member]
Assets, Current
OfficeAndLaboratoryEquipment
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Property, Plant and Equipment, Net
Assets, Noncurrent
Assets
Liabilities, Current
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Revenue, Net
Operating Expenses
Operating Income (Loss)
Interest Expense [Default Label]
Nonoperating Income (Expense)
GainLossOnRevaluationOfDerivativeWarrantLiability
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Machinery and Equipment
Increase (Decrease) in Restricted Cash
Net Cash Provided by (Used in) Investing Activities
Repayments of Debt
Repayments of Long-term Capital Lease Obligations
Net Cash Provided by (Used in) Financing Activities
Schedule of Derivative Liabilities at Fair Value [Table Text Block]
Development Stage Enterprise, Deficit Accumulated During Development Stage
CashAndCashEquivalentsDetailsTextuals1Abstract
Finite-Lived Intangible Assets, Gross [Abstract]
Operating Leases, Future Minimum Payments, Due in Rolling Year Five
Operating Leases, Future Minimum Payments, Due in Rolling Year Two
Operating Leases, Future Minimum Payments, Due in Rolling Year Three
Operating Leases, Future Minimum Payments, Due in Rolling Year Four
Operating Leases, Future Minimum Payments Due
LoanAgreementSeptemberRequest2
SeptemberRequestWarrantIssued1
WarrantExercisePriceSeptemberRequest2
FairValueSeptemberRequest
Derivative Liability, Fair Value, Gross Liability
Warrants and Rights Outstanding
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
DisclosureOfCompensationRelatedCostsSharebasedPayments2Abstract
NoncashCompensationExpense
TotalUnrecognizedCompensationExpense1
Fair Value Assumptions, Expected Dividend Rate
Fair Value Assumptions, Expected Volatility Rate
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1
Temporary Equity, Redemption Price Per Share
WarrantsDetailsOutstanding
SharesDetails
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber1
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted1
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAbstract
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
CommonStockDetailsNarrativeAbstract